30K iOS Apps Tracked Updated 12 min ago Revenue Forecasts
Add an app Create Account Sign In
Home

Top 300 Pharmacy Drug Cards 22

0
Quality Score
Niche

Top 300 Pharmacy Drug Cards 22

Low confidence
— App Store rating
✍️ Bumetric analysis
“

Top 300 Pharmacy Drug Cards 22 is an iOS app from Usatine & Erickson Media LLC in the Education category, currently rated — across few ratings. Initial signal reads as no scraped reviews yet: judgment based on metadata only.

Quality Score is 0: Niche (micro-niche or pre-traction stage). For a Education app, that means micro-niche or pre-traction stage. The full BU Investment Matrix below scores 8 dimensions including monetisation, growth, and operational risk.

Track changes month-over-month in the Performance section below: live snapshot history and revenue forecast included.

💰 Monthly revenue · now vs forecast
● Right now
$5.0K
per month
→
12-mo forecast
$5.2K – $10.8K
per month
→
24-mo forecast
$6.4K – $19.2K
per month
MID tier
💡 Grow this revenue
Free AI audit of this app’s store listing
  • Title & subtitle keyword fit
  • Description hook & conversion structure
  • Screenshots, ratings, reviews strategy
Run free AI audit →
Typical impact: +2-5× organic installs
🔔Notify me when this app's revenue changes by

📊 Performance Tracking LIVE

7 snapshots on record
idle
0%
Rating
—
Reviews
0 reviews
Forecast Revenue / mo
$5.0K
Snapshots tracked
7
since Mar 2026
ONE-TIME · BUILD 💰 Estimated build cost
$110K
↳ What it cost to build · not monthly revenue
Likely range $80K – $150K
$25K · MVP floor $100K · indie scale $500K+ · studio build
📈 Pays back in ~1.8y at current MRR

Synthetic estimate. Inputs: category complexity, file size, screen count, monetization layer, platform reach, age × team-size proxy. Calibrated against 2024-2026 indie-agency rate surveys. Full math + source list on /methodology.

Where the money goes
🧱 MVP baseline (design + 1-store ship) +$28K
📱 5 unique screens × $4.5K +$22K
📦 Asset bundle (95 MB) +$17K
⚙ Education complexity ×1.20 +$13K
⚙ 5.0y maintenance × ~1-person team +$30K
Total estimate $110K
ONE-TIME · EXIT VALUE 💵 Estimated acquisition value
$100K
↳ What it would sell for · not monthly revenue
Marketplace range $75K – $125K · 19× MRR multiple
💸 ~0.9× build cost (under-water)

Synthetic estimate. Multiple band derived from ad-supported + age, rating quality, category demand, and user-base maturity. Calibrated against 2024-2026 indie-app-marketplace closed-deal medians. Full math + comparable deal list on /methodology.

How the multiple was built
📺 Ad-supported base 15× MRR
📅 5.0y proven track record +20%
🏷 Education category multiple +6%
Final multiple 19× MRR
🛠 Estimated tech stack
🍎
Native iOS (SwiftUI)
Medium confidence · 60%
Also possible
React Native Flutter

Heuristic guess from app bundle size, category, store description signals, and release-date stack era. Bumetric does not disassemble binaries — for binary-level certainty you would need an SDK intelligence tool or the manifest itself. Reasoning chain on the right. Full ruleset on /methodology.

Signals we read
📦 App bundle size 95 MB
🏷 Category context Education
📦 Mid-large iOS bundle → Likely native SwiftUI (post-2020 era)
💀 Maintenance status
Likely abandoned
88%
Last shipped 2024-04-04 · 962 days ago
0 · Active 50 · At risk 100 · Abandoned

Heuristic risk score from time-since-last-update + ratings velocity proxy + Editor's Choice / curated featuring signals. Calibrated against 2024-2025 app-store ranking decay reports. Not a guarantee — a quiet app with a healthy codebase looks the same as an abandoned one until something breaks. Full math on /methodology.

Risk signals
📅 2y+ since last update Likely abandoned
Verdict Likely abandoned
🔬

How we forecast this revenue

MEDIUM CONFIDENCE
Baseline
$5.0K/mo · ML-estimated from 234 triggers
Growth rate
+4.0% MoM · MID tier baseline (compound monthly)
Direction
Headwinds: rating drift may slow acquisition
6 months
$4.7K – $7.9K
12 months
$5.2K – $10.8K
24 months
$6.4K – $19.2K
Compound growth at +4.0% MoM (tier baseline for MID). Range widens with horizon — typical noise band ±25% at 6mo.. Ranges widen with horizon — distant futures carry more uncertainty.
📊

BU Investment Matrix

Stalled · 38/100MID TIERno growth momentum
RevenueQualityMarketGrowthMoatSafetyFounderMonetiz.
Revenue Strength
3.7
Product Quality
0.0
Market Position
2.0
Growth Velocity
5.0
Defensibility
6.2
Operational Safety
7.0
Founder Strength
5.3
Monetization Maturity
1.0
  • 💰 Revenue: Modest — $3K - $7K/mo · MID tier · medium confidence, trajectory unclear.
  • ⭐ Quality: None★ across 0 reviews — weak — significant quality concerns.
  • 📍 Market: Not yet charting in any of the 9 monitored markets.
  • 📈 Growth: ⚠ last update 962d ago — possibly dormant.
  • ⚠️ Risk: Moderate — dormant (962d since update).
🎯 For competitors: Mixed picture. Worth competing if you have a clear UX or pricing edge — otherwise crowded segment.
💵 For acquirers: Estimated asking range 18-32× monthly = $90K-$160K.
Composite of 8 dimensions computed deterministically from public signals — no LLM, every score traces back to a measurable input. Default weights shown; "compete" / "acquire" / "invest" lenses re-weight without re-fetching.
Range:

💰 Forecast Revenue / mo

MODEL
Revenue forecast computed from BU's 234 trigger model on each snapshot. Calibrated against ground-truth from 58 verified-revenue apps.
🔬Forecast Breakdown — Why This Estimate?Top 3 of 3 triggers
Our ML model uses 200+ signals from public data. These are the most influential for this app:
Paid app ($49.99)METRIC
+$2,800
Established app (5y old)METRIC
+$800
Single-language (English only)METRIC
−$400
METRIC = structural app data · REVIEW = mined from user reviews · ✓ VERIFIED = Stripe-verified anchor (TrustMRR)

📈 Reviews Growth

LIVE
Cumulative review count from first BU snapshot. Each point = a tracked update.

⭐ Rating Trend

LIVE
Average rating evolution. Updates with each new review batch.

🆕 What's New · v1.1

Updated color of navigation bars

Profile & Insights

Everything we know — and don't — about this app and its company.

Identification

App name
Top 300 Pharmacy Drug Cards 22
Developer
Usatine & Erickson Media LLC
Bundle ID
Not found
App Store URL
Open in App Store
Category
Education
Content rating
17+
Languages
EN

Company

Website
Not found
Tagline
Not found
Description
Not found
Founded
Not found
HQ / Address
Not found
Employees
Not found
Logo
Not found

Revenue

Reported revenue signal / mo
Not found
AI revenue estimate / mo
Not found
AI annual estimate
Not found
Model estimate / mo
$5.0K/mo
Top-grossing rank
Not found
All-time revenue
Not found
Pricing
Not found

Founder

Founder data not yet collected for this app.

Funding

Funding data not yet collected for this app.

Press & Links

Press & Links data not yet collected for this app.

Contacts & Socials

Contacts & Socials data not yet collected for this app.
🌍Geographic ReachNot ranked
This app is currently outside the top 100 grossing in all 9 countries we monitor (US, UK, DE, FR, JP, CA, AU, BR, IN). Niche or new apps often launch this way — popularity rankings appear once daily revenue clears the regional threshold.
Profile is built from iTunes Lookup + developer site scrape + ML revenue model. Empty fields show "Not found" — additional sources (Crunchbase, X, IndieHackers, Acquire.com) coming.

📝 About this app

The quickest, most efficient way for mastering critical facts about common drugs

Perfect for NAPLEX and course review, McGraw Hill's 2022-2023 Top 300 Pharmacy Drug Cards is the most concise and up-to-date resource for building a solid knowledge base of the most commonly used drugs.

Each card includes:
• Generic and common name
• Dosage Forms
• Approved Dose and Indications
• Off-Label Use
• Contraindications
• Adverse Reactions
• Drug Interactions
• Monitoring Parameters
• Medication Safety Issues and Black Box Warnings
• Strong focus on patient safety… View full description on the official store →
App Specs
🔐 Own this app? Claim & verify MRR →
💾 95 MB🔞 17+📱 iOS 10.0+🔖 v1.1🔄 updated 2y ago🌐 EN📂 Education💰 Paid🚀 Launched 2021 (5y old)
🌍

Multi-Country Performance

Available in 9 of 9 monitored markets
MarketRatingReviewsCurrent version
🇺🇸 US0★0—
🇬🇧 GB0★0—
🇩🇪 DE0★0—
🇫🇷 FR0★0—
🇯🇵 JP0★0—
🇨🇦 CA0★0—
🇦🇺 AU0★0—
🇧🇷 BR0★0—
🇮🇳 IN0★0—
🔔

Track this app’s revenue

FREE
Get an email when revenue moves by your threshold. No spam, unsubscribe in one click.

📝 Description

95
BU Score · Transcendent

More by Usatine & Erickson Media LLC

View all →
📦 Portfolio summaryINDIE studio
6apps·$30K/mocombined
✓ Diversified — top app contributes 17%; risk spread across portfolio

Similar apps in Education

About this analysis
ZCAnalyzed by Zakhar Chumak · founder, Bumetric·Full methodology·Low confidence

Why low confidence: only 0 ratings · no founder-verified revenue (model estimate only) · revenue figure is directional only.

📌 Final verdict — read this before you trust the numbers above

Top 300 Pharmacy Drug Cards 22 is a very early-stage iOS app in the education space with weak public traction — only 0 ratings, no founder-verified MRR, and not ranked in any monitored grossing chart. The app appears to be monetised, but public signals are too sparse for a precise revenue estimate.

Bottom line: treat all revenue, audience and acquisition-value numbers on this page as directional only — not founder-verified facts.

❓ Frequently Asked Questions

6 answers · auto-generated from this app's public data
How much does Top 300 Pharmacy Drug Cards 22 make per month?▴
Low-confidence model estimate. Top 300 Pharmacy Drug Cards 22 has only 0 App Store ratings, so our revenue model has very little signal to work with — treat the ~$5.0K/mo figure as directional only, not a verified MRR. No founder-verified revenue data is available for this app. See methodology for the formula and confidence bands.
What apps are like Top 300 Pharmacy Drug Cards 22?▴
Browse the full Education category catalog to find similar apps with revenue, build cost, audience and tech stack data. Each /p/{slug} page also shows a Compare side-by-side widget with three peer apps from the same niche.
What is Top 300 Pharmacy Drug Cards 22 built with?▴
Our heuristic places Top 300 Pharmacy Drug Cards 22 on the Native iOS (SwiftUI) stack (Medium confidence, 60%). Signals: app bundle size, category context, store-description markers, release-date era. We don't disassemble binaries. Alternative possibilities: React Native, Flutter.
Is Top 300 Pharmacy Drug Cards 22 still actively maintained?▴
Maintenance status: Likely abandoned (88% abandonment risk). Last shipped version was 2+ years ago. The risk score combines time-since-last-update with Editor's Choice / curated featuring + user-base maturity adjustments.
When was Top 300 Pharmacy Drug Cards 22 last updated?▴
Top 300 Pharmacy Drug Cards 22 last shipped a new version on 2024-04-04 — more than 2 year(s) ago. This is the date Apple / Google last accepted a new build, not a content-only push.
Who makes Top 300 Pharmacy Drug Cards 22?▴
Top 300 Pharmacy Drug Cards 22 is published by Usatine & Erickson Media LLC on the Apple App Store. See the full publisher portfolio (other apps by the same developer) via the More by developer block on the product page above.